1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

19 Mar 2024
Admin
News Article

Biotheus and Hansoh Pharma Prolong Partnership for EGFR/cMET Antibody

Biotheus and Hansoh Pharma Expand Partnership for EGFR/cMET Bispecific Antibody-Drug Conjugate Development

Overview

Biotheus Inc. and Hansoh Pharmaceutical Group Co., Ltd. have jointly announced an extension of their strategic collaboration in the development of biologics for oncology and inflammatory diseases. This collaboration builds upon their partnership since 2022. Under the new agreement, Biotheus will grant Hansoh Pharma a license to use its proprietary anti-EGFR/cMet bispecific antibody, PM1080/HS-20117, for the development of antibody-drug conjugate products (ADC Product).

Terms of the Agreement

According to the terms of the agreement, Hansoh Pharma will gain exclusive worldwide rights to utilize PM1080/HS-20117 for the development, production, and commercialization of ADC Products, with the option for sublicensing.
In return, Biotheus will receive upfront payments and milestone achievements for ADC Product, as well as royalties based on global net sales from Hansoh Pharma.

About PM1080/HS-20117

PM1080/HS-20117 is currently in phase I clinical trials and is designed as a 1+1 heterodimeric structure of EGFR/cMet bispecific antibody, targeting tumor antigens EGFR and cMet to inhibit tumor growth and survival.

Words from CEO: Biotheus

Mr. Xiaolin Liu, Co-founder, Chairman, and CEO of Biotheus, expressed appreciation for Hansoh's confidence in PM1080's potential, emphasizing the benefits of bispecific ADCs for tumor treatment.
He highlighted the collaboration's goal of developing a novel EGFR/cMet bispecific ADC for cancer patients worldwide.

Words from CEO: Hansoh

Ms. Eliza Sun, Executive Director of the Board at Hansoh, also expressed enthusiasm for the expanded partnership, highlighting the combination of Hansoh's ADC Platform technology with Biotheus' bispecific antibody.
She expressed confidence in their ability to provide innovative treatment options for cancer patients globally, leveraging their expertise in clinical development, commercialization efforts, and external partnerships.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!